in the acute inflammatory phase of MI is a critical determinant of the degree of adverse remodeling leading to HF. [18] [19] [20] Therefore, strategies that enhance efficient resolution of inflammation and prevent unnecessary further cell death may be useful in slowing the progression to HF.
Inflammation after MI is an important component of healing after tissue injury. 21 A diverse population of bone marrow and spleen-derived immune cells are recruited to the heart after ischemic injury and promote clearance and repair of damaged myocardium. 22, 23 The innate immune response has beneficial activity in the healing heart [24] [25] [26] ; however, maladaptive cardiac inflammation can also be detrimental. 27, 28 Recent studies have identified innate monocyte subsets to be differentially responsible for phagocytic and repair functions in the heart. 22 Beyond the identification of these cellular subsets, the molecular pathways responsible for dead-cell clearance in cardiac tissue remain unknown. Professional phagocytes interact with the myocardium in numerous capacities, including proteolysis, 29 dying/dead-cell clearance, angiogenesis, and scarring. 30 In particular, inefficient removal of dead cardiac tissue has been linked to the progression of HF. 28, 30 Professional phagocytes express multiple efferocytosis receptors to efficiently clear dying cells and to prevent the release of autoantigens. 31 In this study, we interestingly discover that the macrophage efferocytosis receptor myeloid-epithelial-reproductive tyrosine kinase (MERTK), which has been characterized by our group and independent laboratories, 8, [32] [33] [34] [35] is specifically required for the clearance of dying adult cardiomyocytes. Furthermore, we test for the first time the extent to which molecular pathways required for efferocytosis contribute to heart repair. Mertk +/+ and Mertk −/− mice were subjected to experimental MI and assessed for apoptotic cardiomyocyte accumulation, in vivo efferocytosis, inflammation resolution, infarct size, ventricular remodeling, and systolic function.
Methods
Briefly, CD36 −/− , 36 LRP fl/fl LysMcre, 37 and Mertk −/−38 bone marrow-derived mouse macrophages were cocultivated with primary adult mouse cardiomyocytes and efferocytosis assessed ex vivo. Parallel assays were performed in which Mertk was reconstituted into cells to test sufficiency. In vivo, Mertk +/+ and Mertk −/− mice and bone marrow chimeras were subjected to MI after permanent occlusion of the left anterior descending artery. Subsequently, Mertk expression (mRNA and protein), apoptotic cell accumulation (terminal deoxynucleotidyl transferase dUTP nick-end labeling [TUNEL]), in situ efferocytosis, infarct size (triphenyl tetrazolium chloride and collagen staining), inflammatory parameters (chemokine and cytokine mRNA and macrophage accumulation), and ventricular remodeling and cardiac function (echocardiography) were measured. The identification of glycosylated solMER in heart extracts was corroborated by the addition of an N-glycanase.
Statistical Analysis
Results are presented as mean±SEM. Differences between multiple groups were compared by ANOVA as appropriate and as indicated (2-way ANOVA and Bonferroni posttest), and differences between 2 groups were compared by unpaired Student t test (indicated by #). Two-way repeated measures ANOVA was used to evaluate the statistical significance of data acquired from the same animal over multiple time points. A value of P<0.05 was considered to be significant as indicated by * or #. Stated n values are biological replicates. Survival distributions were estimated using the Kaplan-Meier method and compared by the log-rank test.
An expanded and detailed Materials and Methods section is available in the Online Data Supplement.
Results

Dying Cardiomyocytes Are Engulfed by Macrophage Phagocytes
Previous studies have examined the consequences of macrophage and cardiomyocyte cocultivation 39 ; however, and to the best of our knowledge, the study of cardiomyocyte engulfment by phagocytes ex vivo has not been reported. To examine how cardiomyocytes are ingested by macrophages, we cocultivated dying primary adult mouse cardiomyocytes with bone marrow-derived macrophages. After rinsing away nonengulfed cells, we could find evidence that ingestion of fluorescent cardiomyocyte bodies, indicated by red inclusions in green-labeled macrophages, occurred as early as 20 minutes after incubation ( Figure 1A ). When cocultivated at equivalent phagocyte:apoptotic-target ratios, the typical percentage of macrophages positive for ingestion of cardiomyocyte bodies were inefficient 20% to 25% compared with 30% to 40% under equivalent phagocyte:target ratios of apoptotic Jurkat cells, which are often used for in vitro efferocytosis studies. 1 Parallel confocal micrographs indicated that our rinsing protocol removed bound and noningested cardiomyocytes and that internalization was specifically measured with this protocol. Furthermore, preincubation of phagocytes with cytochalasin D blocked efferocytosis by disrupting actin polymerization (Online Figure IA ).
Identification of MERTK as a Receptor Specifically Required for Efferocytosis of Cardiomyocytes
A number of efferocytosis receptors have been identified in macrophages, including CD36, low-density lipoprotein receptor-related protein 1 (LRP), and MERTK. 38, 40, 41 To examine the potential role of these surface integral membrane proteins during efferocytosis of cardiomyocytes, we cocultivated macrophages from Cd36 −/− , LRP-deficient (LRP fl/fl , LysMCre), or Mertk −/− mice with primary adult cardiomyocytes. Apoptosis was induced in cardiomyocytes by subjecting cells to ischemia (hypoxia and serum deficiency). Results were compared with littermate controls (Cd36 +/+ , LRP fl/fl , and Mertk +/+ , respectively). The data show that Cd36 and LRP deficiency did not significantly affect engulfment; however, cardiomyocyte-associated fluorescence was greatly reduced (>70%) in Mertk −/− relative to Mertk +/+ phagocytes ( Figure 1B ). Similar requirements for phagocyte Mertk were found during ingestion of the murine cardiomyocyte cell line HL-1 42 (Online Figure IB ). To determine whether Mertk is sufficient for the engulfment of dying cardiomyocytes, we transfected Mertk DNA into human embryonic kidney-293A cells, which do not express Mertk. 43 Indeed, relative to cells transfected with empty vector (pIRES2-EGFP), ectopic expression of Mertk conferred the capacity of human embryonic kidney cells to engulf cardiomyocytes ( Figure 1C necrosis factor-α, and this was increased in the absence of Mertk ( Figure 1D ). Thus, macrophage Mertk specifically is necessary and sufficient for efferocytosis of cardiac cardiomyocytes and suppresses cardiomyocyte-induced inflammation.
Exploring the Role of Mertk in the Heart
We sought to determine the physiological relevance of our findings in the heart. We first examined cardiac geometry and function from Mertk +/+ and Mertk −/− mice. Baseline indexes of these mice are listed in Online Table I . Briefly, no significant differences in body mass or cardiac mass were found. By echocardiography, cardiac dimensions and contractile performance between adult Mertk +/+ and Mertk −/− mice were also initially similar. Microscopic examination did not reveal significant changes in cardiomyocyte size, apoptosis (by TUNEL staining) or in the number of immune cells in adult mice at baseline.
Identification of Mertk Expression in Infarcted Myocardium
We determined the extent of Mertk expression in the unique hypoxic milieu of the post-MI heart. Figure 2 outlines a temporal and spatial analysis of Mertk expression in mouse myocardial tissue after wounding. Injury was induced by permanent occlusion of the left anterior descending artery, as we have described recently. 44 Semiquantitative real-time polymerase chain reaction showed that noninfarcted hearts had relatively low Mertk expression. In contrast, we discovered that coronary occlusion led to a significant induction of Mertk mRNA at 7 days after MI (Figure 2A) . A time-course analysis by quantitative real-time polymerase chain reaction in infarcted left ventricle versus remote right ventricle revealed increases in left ventricular (LV) Mertk as early as day 3 after MI and peaking at day 7 ( Figure 2B ). By laser capture microdissection of myocardial tissue sections, increases in Mertk mRNA were focused within the inflammatory border zone of the infarct ( Figure 2C ). MERTK protein levels paralleled mRNA ( Figure 2D ), and as expected, MERTK immune reactivity was colocalized with F4/80 + macrophages ( Figure 2E ). We 45 in complementing Ly6c HI monocyte-mediated myocardial clearance, as previously reported 22 ( Figure 2F ). To assess the causal role of Mertk during MI, Mertk +/+ and Mertk −/− C57BL/6 littermates were subjected to MI as above and examined ≤28 days after infarction. No significant differences in mortality (7.3% in Mertk +/+ versus 9.1% in Mertk −/− ; P=0.32) or cardiac rupture were measured between experimental groups at the time points examined. After MI, increases in heart mass were as expected, and heart-to-tibia-length and heart-to-body weight ratios were not different between the 2 groups (Online Table I ). Also, no differences in baseline blood leukocyte or monocyte subsets were discovered (Online Figure II ).
Mertk Deficiency Does Not Affect Initial Myocardial Monocyte Recruitment but Leads to Markers of Delayed Inflammation Resolution
To determine the effect of Mertk deficiency on inflammation after MI, we examined monocyte levels and inflammatory cytokines. Online Figure IIIA shows that loss of Mertk did not affect absolute levels of monocytes in the heart before and after MI. Similarly, the ratio of Ly6c HI and Ly6c LO monocytes was not affected ( Figure 3A ). Postinfarction inflammatory cells are recruited by rapid and transient induction of chemokine mRNA. 46 After MI, Ccl2 (Mcp-1) was induced in wildtype mice with timely repression as expected. 23 Mertk −/− mice induced similar levels of chemokine and cytokine mRNA at early time points but exhibited increases in Tnf-α and Il-6 and reduced levels of Il-10 at later time points ( Figure 3B ), consistent with a defect in inflammation resolution.
Increased Accumulation of Apoptotic Cardiomyocytes Coincides With a Reduced Index of Efferocytosis in Hearts of Mertk −/− Mice After MI
Numerous reports have linked cardiomyocyte apoptosis to post-MI heart repair; however, studies of cardiomyocyte fate after cell death are comparatively lacking. To first determine whether Mertk is required for the accumulation of apoptotic cardiomyocytes in vivo, we measured levels of cardiomyocyte (Desmin + ) apoptosis (TUNEL + ) at days 3, 5, and 7 after infarction in Mertk +/+ and Mertk −/− mice. Cardiomyocyte apoptosis ( Figure 4A ) was increased ( Figure 4A , bar graphs) as expected after MI. However, no significant difference between experimental groups was found at day 3 after MI, consistent with a lack of effect of Mertk on initial infarct size ( Figure 5 ). This was not the case at later time points, which coincided with maximal expression of MERTK in wild-type hearts, because Mertk −/− hearts at days 5 and 7 exhibited significantly increased TUNEL + cardiomyocytes relative to control. To explore the possibility that elevations in apoptosis might occur through enhanced susceptibilities to apoptosis, we isolated adult mouse cardiomyocytes and subjected cells to ischemic stress. Importantly, cardiomyocytes from Mertk +/+ and Mertk −/− mice exhibited similar kinetics of staurosporine-and ischemiainduced cell death (Online Figure IV) . Requirements for MERTK in vivo were not generalizable to the accumulation of neutrophils (Online Figure IIIB) , consistent with selective MERTK expression on Ly6c LO phagocytes, which emerge after reductions in myocardial neutrophil levels. Furthermore, Mertk deficiency did not affect the levels of TUNEL + CD68 macrophages or TUNEL + smooth muscle actin myofibroblasts at 7 days after MI (Online Figure V) . To directly assess whether accumulations of apoptotic cardiomyocytes were associated with defects in phagocytosis processing in vivo, we adapted a previously established methodology reported by our group and independent laboratories 32,47-50 and quantified tissue efferocytosis in situ. Similar to our ex vivo analyses, we enumerated the percentage of cardiomyocyte-associated macrophages by costaining myocardial sections for cardiomyocyte Desmin and macrophage CD68. Figure 4B shows yellow cardiomyocyte Desmin signal colocalized with CD68 + phagocytes in border zones of the infarct. The quantified results of our blinded analysis are shown on the right. Two independent investigators achieved >91% concurrence after 15 hearts per group. In areas of equivalent phagocyte density, the measured percentage of Desmin-associated CD68 + cells was reproducibly and significantly reduced in Mertk −/− mice at day 5 after MI. Similar findings were found with the alternative cardiomyocyte marker α-actinin. These data are consistent with a defect in efferocytosis contributing to apoptotic cardiomyocyte accumulation.
Deficiency of Mertk Leads to Increased Infarct Size
The extent of myocardial apoptosis is associated with the degree of myocardial necrosis, or infarct size, and infarct size is a major determinant of patient prognosis. 51 Thus, we were curious whether deficiencies in apoptotic cardiomyocyte clearance might contribute to larger infarcts. To quantify infarct areas in hearts of Mertk +/+ and Mertk −/− mice, we performed triphenyl tetrazolium chloride staining to differentiate live from dead tissue after MI, as we have described previously. 44 Importantly and for all time points assessed, the areas of endangered/ischemic myocardium (ie, area at risk) as assessed by dye perfusion were similar between genotypes, indicating equal and consistent levels of surgically induced ischemia. The data show that, similar to levels of apoptotic cells (Figure 3 ), LV infarct size at day 3 after MI was not statistically different between Mertk +/+ (31±3%) and Mertk −/− mice (30±4%; P=0.612; Figure 5A ). We hypothesized that if defective efferocytosis contributes to infarct area through secondary cellular necrosis, then accumulations in apoptotic cardiomyocytes should precede changes in infarct size. Indeed, infarct size at day 7 ( Figure 5B ) was significantly enlarged with Mertk deficiency. In addition, serum creatine kinase, an enzyme contained in viable myocytes and released into the bloodstream during myocardial injury, was also increased in the absence of Mertk (data not shown). These data are consistent with the hypothesis that noncleared apoptotic cardiomyocytes, conferred by defective Mertk, contribute, at least in part, to further loss of cardiomyocytes and increase of infarct necrosis in injured hearts.
Mertk Deficiency Promotes Adverse Ventricular Remodeling and LV Functional Deterioration After MI
Morphometric analysis of Mertk −/− mice 28 days after MI corroborated our findings of increased infarct size at day 7. Figure 6 shows that LV collagen area, as determined by Masson trichrome staining, was significantly increased in Mertk −/− mice compared with wild type (10.38±0.78 versus 16.68±1.32; P<0.05). In addition, deficiency of Mertk led to thinner LV walls. Interestingly, picrosirius red staining under polarized light revealed that the degree of collagen cross linking was also reduced in Mertk −/− mice (data not shown). We asked whether Mertk might contribute to heart performance after MI. As assessed by 2-dimensional M-mode echocardiography, infarction led to expansive LV remodeling and reduced systolic function in all mice as expected. Whereas LV volumes were similar between groups at 1 week after MI, Mertk −/− hearts exhibited enlarged LV end-diastolic volume and end-systolic volume by 28 days ( Figure 7A ). Increased LV remodeling was accompanied by further functional deterioration. Mertk −/− mice had significantly reduced systolic performance as indicated by depressed fractional shortening and ejection fraction. Ventricular hemodynamic assessments also showed reductions in arterial systolic pressure and contractility in Mertk −/− mice after MI (Online Table I ).
To confirm that worsened heart contractility was the result of an infiltrating cell type and to evaluate the reproducibility of our findings, we generated Mertk −/− bone marrow chimeric animals after γ-irradiation, as we previously described. 52 Protein and mRNA analysis of bone-marrow-derived cells after engraftment validated successful depletion of myeloid Mertk in recipient animals (Online Figure VI) . Similar to whole-body knockouts, deficiency of Mertk in bone marrow also led to suppressed ejection fraction and fractional shortening ( Figure 7B, bottom 
Identification of Low-Molecular-Weight MERTK Products After MI
Our studies of targeted Mertk gene deficiency led to a curiosity of natural mechanisms of MERTK regulation in the injured heart. Recent reports from our group and independent laboratories have characterized the inhibition of efferocytosis after proteolysis of an ectodomain fragment of MERTK, known as solMER. 43, 53 As shown in Figure 8 , Western blot analysis identified significant MER immune reactivity in a band consistent with the molecular weight of glycosylated solMER. 53 solMER was not detected in Mertk −/− mice. Furthermore, removal of N-linked sugars by glycanse treatment of myocardial extract led to collapse of this band to the precise molecular weight of the predicted 60-kDa solMER ectodocmain. These data interestingly suggest a natural mechanism MERTK inactivation post MI.
Discussion
In light of decades of observations linking mobilization of the innate immune system to the repair of injured myocardium, the data herein provide strong support for the hypothesis that immune cell-derived efferocytosis pathways bridge clearance of dying cardiac cells to subsequent repair and, in turn, mitigate progression to HF. Through the use of a murine model of experimental MI, we report that Mertk deficiency in vivo leads to the accumulation of apoptotic cardiomyocytes and a reduced index of in vivo efferocytosis. Suppressed efferocytosis preceded increases in myocardial infarct size and led to subsequent delayed inflammation resolution. Importantly, Mertk deficiency led to compromised systolic performance. Ex vivo, Mertk was specifically necessary and sufficient for the efferocytosis of dying cardiomyocytes. These findings suggest that, in addition to proinflammatory pathways that mobilize immune cells to the heart, pathways involved in resolution of inflammation 30, 54 also play a key role in the healing heart. Furthermore, our findings are in line with previous reports identifying requirements for Mertk during the clearance of apoptotic cells in atherosclerosis, 9, 12, 55 thereby expanding the cardiovascular role of Mertk in a molecular continuum that connects pre-and post-MI events. This is interesting in that acute inflammation after MI is significantly lesser in duration compared with the chronic inflammation of atherosclerosis. We speculate that loss of precious nonregenerative cardiomyocytes may underlie a heightened sensitivity to defective efferocytosis. The findings of this study raise the important question of whether inefficiencies of efferocytosis occur naturally and are of significance in human clinical MI. Previous reports by Frangogiannis et al 28 show defective necrotic cardiomyocyte clearance in aged experimental animals and an association with worsened heart repair. However, this was also associated with a dampened immune response, preventing conclusions to be made on the intrinsic capacity of aged phagocytes for efferocytosis. During aging, it is interesting to note that phagocytes harvested from older animals exhibit reduced efficiencies of efferocytosis, the mechanisms of which are as yet unclear. 48 Similarly, Nahrendorf and Swirski 27 have shown that hyperlipidemia is associated with delayed elimination of necrotic myocardium. In this study, high cholesterol levels were associated with Ly6c HI monocytosis and an activated monocyte phenotype. Similarly, increases in circulating monocyte levels have been independently associated with poor patient prognosis after MI. 56 If clearance of dying cells after MI is inherently inefficient or compromised in aged or hyperlipidemic patients, what mechanisms may be responsible? Although the goal of the current study was to deplete inflamed myocardium of a known efferocytosis receptor, it is also possible that MERTK could be rendered naturally dysfunctional in the setting of disease or genetic risk factors. For example, polymorphisms in Mertk are associated with increased autoimmune inflammation in diseases such as lupus. 57, 58 In addition, a disintegrin and metalloprotease domain metallopeptidase 17, which cleaves MERTK into a soluble inhibitory receptor, 43, 53 is increased during MI. 59 This may explain the identification of solMER in our murine extracts ( Figure 8 ) and further may provide the impetus for investigation of human MI specimens. MERTK activity may also be limited by availability of its ligand Gas6, which is required for binding to apoptotic cells. 60 Thus, it is tempting to speculate that studies herein mimic natural events and that limited evolutionary pressure during MI in the elderly may provide a window for therapeutic improvement.
It is important to consider other effects of Mertk within this study. For example, in some cases, Mertk-deficient mice have a heightened inflammatory response. 38 In this study and previous reports, 32 the evidence does not support increased systemic or cardiovascular inflammation at baseline (Online Table I ). In addition, initial inflammatory chemokine/cytokine levels, as well as initial recruitment of Ly6c HI cells (Figure 3) , were similar in all experimental groups. Furthermore, increased inflammatory levels and reduced interleukin-10 levels did not proceed to accumulation of apoptotic cardiomyocytes (Figure 4 ), all consistent with defects in the resolution arm of inflammation. Indeed, defective efferocytosis, in general, is associated with inflammation that is secondary to postapoptotic cellular necrosis. 5 Thus, these findings argue for a direct role of Mertk within the ischemic myocardium. It will be important in future studies to examine the effects of defective efferocytosis or Mertk deficiency on other critical components of myocardial healing and remodeling. For example, elevated inflammation can further and directly affect ventricular remodeling by regulating myocyte phenotype transition, activation of matrix metalloproteinases, and transforming growth factor-β production. 30, 61 Regardless of the results of future studies on the mechanisms of MERTK in heart repair, the data reveal the importance of a single molecule in a critical stage of post-MI heart repair, namely infarct size and reduced systolic function.
It is significant to mention that even in the absence of Mertk, accumulation of apoptotic cells eventually did subside; therefore, other efferocytosis receptors and pathways almost certainly are involved in the heart. For example, thormobospondin-1, which prevents infarct expansion through its effects on extracellular matrix, 62 is also required for apoptotic cell processing in vitro and therefore might also mediate its beneficial effects in the heart through efferocytosis. 63 Also of interest is the effect on efferocytosis by reperfusion after ischemia, the mechanisms of which may be distinct. Although a permanent occlusion model was used in this study to optimally examine the effects of Mertk on ventricular remodeling, future studies will examine the role of Mertk during reperfusion injury to explore therapeutic potential. Along these lines, the potential of harnessing clearance pathways in the heart has already been explored because infusion of phosphatidylserine liposomes improves infarct repair through modulation of cardiac macrophage function. 64 Phosphatidylserine is the canonical eat-me signal that is recognized by phagocytes before efferocytosis.
The data herein identify bone marrow-derived Mertk as a significant determinant of cardiac repair and function after acute MI. From a broader perspective, these studies implicate efferocytosis as a causal modulator in the healing heart and merit the investigation of other myocardial efferocytosis pathways. Future studies are warranted in the setting of risk factors, including aging and hyperlipidemia, as described above. Potential benefits of inflammation-resolution pathways after MI may also extend beyond HF and to secondary MI events Immunoblot of myocardial extracts 5 days after MI in wild-type mice. Three separate mice (MI1, MI2, and MI3) were subjected to ligation of the left anterior descending artery. Subsequently, myocardial extracts were interrogated for immunoreactivity against a monoclonal anti-MER (ectodomain specific) antibody. MI3 was also treated with a glycanse before electrophoresis.
downstream of atherosclerotic plaque rupture. 65, 66 Thus, these studies provide a proof of principle for the therapeutic potential of modulating the post-MI inflammatory response through activation of pathways that link clearance of dying cells to inflammation resolution and heart repair.
